Nexstim Plc announced that it has received an NBS (Navigated Brain Stimulation) 6 system order from the Center for Integrative Neuroscience, a new clinic located in Traverse City, Michigan. Released earlier in 2023, the NBS 6 is a new generation Nexstim system that is FDA-approved for the treatment of major depressive disorder (MDD) and CE-marked for the treatment of MDD and chronic neuropathic pain. The modular product design allows for an expansion of system capabilities over time.

The NBS 6 utilizes Nexstim?s nTMS (navigated transcranial magnetic stimulation) technology, enabling high-precision and accurate targeting of the TMS to the brain.